Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts

Journal of Functional Foods

Volumn 19, Issue , 2015, Pages 225-235

  González Sarrías, Antonio ^a   García Villalba, Rocío ^a   Núñez Sánchez, M Ángeles ^a   Tomé Carneiro, Joao ^a   Zafrilla, Pilar ^b   Mulero, Juana ^b   Tomás Barberán, Francisco A ^a   Espín, Juan Carlos ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

^b CATHOLIC UNIVERSITY OF MURCIA   (Spain)

Author keywords

Bioavailability; Ellagic acid; Pharmacokinetics; Pomegranate; Punicalagin; Urolithins

Indexed keywords

EID: 84946397477     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2015.09.019     Document Type: Article

References (33)

1. Actis-Goretta L., Dew T.P., Lévèques A., Pereira-Caro G., Rein M., Teml A., Schäfer C., Hofmann U., Schwab M., Eichelbaum M., Crozier A., Williamson G. Gastrointestinal absorption and metabolism of hesperetin-7-O-rutinoside and hesperetin-7-O-glucoside in healthy humans. Molecular Nutrition & Food Research 2015, 10.1002/mnfr.201500202.
2. Bala V., Bhardwaj S., Hariharan M.N.V., Kumar R. Analytical methods for assay of ellagic acid and its solubility studies. Journal of Pharmaceutical and Biomedical Analysis 2006, 40:206-210.
3. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., Booth T.D., Crowell J.A., Perloff M., Gescher A.J., Steward W.P., Brenner D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology & Biomarkers Prevention 2007, 16:1246-1252.
4. Daniel E.M., Ratnayake S., Kinstle T., Stoner G.D. The effects of pH and rat intestinal contents on the liberation of ellagic acid from purified and crude ellagitannins. Journal of Natural Products 1991, 54:946-952.
5. Ding Y., Zhang B., Zhou K., Chen M., Wang M., Jia Y., Song Y., Li Y., Wen A. Dietary ellagic acid improves oxidant-induced endothelial dysfunction and atherosclerosis: Role of Nrf2 activation. International Journal of Cardiology 2014, 175:508-514.
6. Espín J.C., González-Barrio R., Cerdá B., López-Bote C., Rey A.I., Tomás-Barberán F.A. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. Journal of Agricultural and Food Chemistry 2007, 55:10476-10485.
7. Espín J.C., Larrosa M., García-Conesa M.T., Tomás-Barberán F.A. Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: The evidence so far. Evidence-Based Complementary and Alternative Medicine: eCAM 2013, 2013:270418.
8. García-Villalba R., Beltrán D., Espín J.C., Selma M.V., Tomás-Barberán F.A. Time course production of urolithins from ellagic acid by human gut microbiota. Journal of Agricultural and Food Chemistry 2013, 61:8797-8806.
9. García-Villalba R., Espín J.C., Aaby K., Alasalvar C., Heinonen M., Jacobs G., Voorspoels S., Koivumäki T., Kroon P.A., Pelvan E., Saha S., Tomás-Barberán F.A. Validated method for the characterization and quantification of extractable and nonextractable ellagitannins after acid hydrolysis in pomegranate fruits, juices, and extracts. Journal of Agricultural and Food Chemistry 2015, 63:6555-6566.
10. Giménez-Bastida J.A., Martínez-Florensa M., Espín J.C., Tomás-Barberán F.A., García-Conesa M.T. A citrus extract containing flavanones represses plasminogen activator inhibitor-1 (PAI-1) expression and regulates multiple inflammatory, tissue repair, and fibrosis genes in human colon fibroblasts. Journal of Agricultural and Food Chemistry 2009, 57:9305-9315.
11. González-Sarrías A., Larrosa M., García-Conesa M.T., Tomás-Barberán F.A., Espín J.C. Nutraceuticals for older people: Facts, fictions and gaps in knowledge. Maturitas 2013, 75:313-334.
12. Hasegawa M., Terauchi M., Kikuchi Y., Nakao A., Okubo J., Yoshinaga T., Hiratsuka H., Kobayashi M., Hoshi T. Deprotonation processes of ellagic acid in solution and solid states. Monatshefte für Chemie 2003, 134:811-821.
13. Hollman P.C. Unravelling of the health effects of polyphenols is a complex puzzle complicated by metabolism. Archives of Biochemistry and Biophysics 2014, 559:100-105.
14. Li B., Harich K., Wegiel L., Taylor L.S., Edgara K.J. Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions. Carbohydrate Polymers 2013, 92:1443-1450.
15. Manach C., Williamson G., Morand C., Scalbert A., Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. American Journal of Clinical Nutrition 2005, 81:230S-242S.
16. Mazur S.P., Nes A., Wold A.B., Remberg S.F., Aaby K. Quality and chemical composition of ten red raspberry (Rubus idaeus L.) genotypes during three harvest seasons. Food Chemistry 2014, 160:233-240.
17. Mertens-Talcott S.U., Jilma-Stohlawetz P., Rios J., Hingorani L., Derendorf H. Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. Journal of Agricultural and Food Chemistry 2006, 54:8956-8961.
18. Naiki-Ito A., Chewonarin T., Tang M., Pitchakarn P., Kuno T., Ogawa K., Asamoto M., Shirai T., Takahashi S. Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis. The Prostate 2015, 75:151-160.
19. Núñez-Sánchez M.A., García-Villalba R., Monedero-Saiz T., García-Talavera N.V., Gómez-Sánchez M.B., Sánchez-Álvarez C., García-Albert A.M., Rodríguez-Gil F.J., Ruiz-Marín M., Pastor-Quirante F.A., Martínez-Díaz F., Yáñez-Gascón M.J., González-Sarrías A., Tomás-Barberán F.A., Espín J.C. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Molecular Nutrition & Food Research 2014, 58:1199-1211.
20. Okla M., Kang I., da Kim M., Gourineni V., Shay N., Gu L., Chung S. Ellagic acid modulates lipid accumulation in primary human adipocytes and human hepatoma Huh7 cells via discrete mechanisms. The Journal of Nutritional Biochemistry 2015, 26:82-90.
21. Quideau S. Chemistry and biology of ellagitannins, an underestimated class of bioactive plant polyphenols 2009, World Scientific Publishing, Singapore.
22. Seeram N.P., Henning S.M., Zhang Y., Suchard M., Li Z., Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. The Journal of Nutrition 2006, 136:2481-2485.
23. Seeram N.P., Lee R., Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clinica Chimica Acta 2004, 348:63-68.
24. Seeram N.P., Zhang Y., McKeever R., Henning S.M., Lee R.P., Suchard M.A., Li Z., Chen S., Thames G., Zerlin A., Nguyen M., Wang D., Dreher M., Heber D. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. Journal of Medicinal Food 2008, 11:390-394.
25. Shahidi F., Ambigaipalan P. Phenolics and polyphenolics in foods, beverages and spices: Antioxidant activity and health effects: A review. Journal of Functional Foods 2015, 10.1016/j.jff.2015.06.018.
26. Stoner G.D., Sardo C., Apseloff G., Mullet D., Wargo W., Pound V., Singh A., Sanders J., Aziz R., Casto B., Sun X. Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days. The Journal of Clinical Pharmacology 2005, 45:1153-1164.
27. Ting Y., Jiang Y., Ho C.T., Huang Q. Common delivery systems for enhancing in vivo bioavailability and biological efficacy of nutraceuticals. Journal of Functional Foods 2014, 7:112-128.
28. Tomás-Barberán F.A., Cienfuegos-Jovellanos E., Marín A., Muguerza B., Gil-Izquierdo A., Cerdá B., Zafrilla P., Morillas J., Mulero J., Ibarra A., Pasamar M.A., Ramón D., Espín J.C. A new process to develop a cocoa powder with higher flavonoid monomer content and enhanced bioavailability in healthy humans. Journal of Agricultural and Food Chemistry 2007, 55:3926-3935.
29. Tomás-Barberán F.A., García-Villalba R., González-Sarrías A., Selma M.V., Espín J.C. Ellagic acid metabolism by human gut microbiota: Consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. Journal of Agricultural and Food Chemistry 2014, 62:6535-6538.
30. Whitley A.C., Stoner G.D., Darby M.V., Walle T. Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid-extensive binding to protein and DNA. Biochemical Pharmacology 2003, 66:907-915.
31. Whitley A.C., Sweet D.H., Walle T. The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. Drug Metabolism and Disposition 2005, 33:1097-1100.
32. Whitley A.C., Sweet D.H., Walle T. Site-specific accumulation of the cancer preventive dietary polyphenol ellagic acid in epithelial cells of the aerodigestive tract. The Journal of Pharmacy and Pharmacology 2006, 58:1201-1209.
33. Wong A.Y.T., Lai J.M.C., Chan A.W.K. Regulations and protection for functional food products in the United States. Journal of Functional Foods 2015, 17:540-551.